Safety and Immunogenicity Outcomes of an Inactivated Viral Vaccine against SARS-CoV-2 (Covaxin®)
Introduction: Bharat Biotech International Ltd in partnership with National Institute of Virology (NIV), has developed an indigenous whole virion inactivated Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) viral vaccine BBV-152 (Covaxin®), formulated with Toll Like Receptors 7/8 agonist...
| প্রধান লেখক: | , , , , , , , |
|---|---|
| বিন্যাস: | প্রবন্ধ |
| ভাষা: | English |
| প্রকাশিত: |
JCDR Research and Publications Private Limited
2022-09-01
|
| মালা: | Journal of Clinical and Diagnostic Research |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://jcdr.net/articles/PDF/16856/57170_CE(AD)_F[SH]_PF1(AG_SS)_PFA(AG_KM)_PN(KM).pdf |